Quick View
| Metric | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue | ¥79.73B | ¥65.6B | +21.5% |
| Operating Income | ¥23.1B | ¥16.21B | +42.4% |
| Ordinary Income | ¥24.54B | ¥14.57B | +68.4% |
| Net Income | ¥15.92B | ¥10.22B | +55.7% |
| ROE (annualized) | 20.4% | 14.6% | - |
Executive Summary
For the cumulative Q2 period of FY2027, operating income growth outpaced revenue growth, with margin expansion being the key highlight. Revenue was ¥79.73B (+21.5% YoY), and operating income was ¥23.1B (+42.4% YoY), lifting the operating margin to 29.0% from 24.7% in the prior-year period. Ordinary income was ¥24.54B (+68.4% YoY), boosted by foreign exchange gains of ¥1.59B, compared with foreign exchange losses of ¥2.37B in the prior-year period. Profit attributable to owners of parent for the interim period was ¥15.84B (+45.7% YoY), achieving double-digit growth after absorbing a ¥2.16B litigation settlement loss.
Factors Behind Financial Performance
【Revenue】Revenue increased 21.5% YoY to ¥79.73B. The Semiconductor and FPD-Related Equipment Business generated ¥79.36B, accounting for 99.5% of total revenue. By customer location, the United States accounted for ¥23.9B (30.0%), China for ¥20.9B (26.2%), and Taiwan for ¥19.41B (24.3%); together, these three regions accounted for approximately 80.5%.
【Profit and Loss】Cost of sales increased 15.3% and SG&A expenses increased 12.1%, both below revenue growth, improving the gross margin to 43.1% from 40.0% in the prior-year period. The SG&A ratio was 14.1%; revenue growth generated operating leverage that drove operating income growth. Below operating income, foreign exchange gains of ¥1.59B were recorded; non-operating income was ¥2.08B and non-operating expenses were ¥0.63B. The ¥2.16B litigation settlement loss was recorded as an extraordinary loss, a temporary factor that resulted in profit before tax of ¥22.37B, below ordinary income. Overall, both revenue and profit increased.
Segment Analysis
The Semiconductor and FPD-Related Equipment Business recorded revenue of ¥79.36B and segment profit of ¥23.97B, representing a margin of 30.2%. Consolidated operating income was ¥23.1B after deducting corporate expenses of ¥0.73B and the ¥0.15B loss from the Life Science Business.
The Life Science Business recorded revenue of ¥0.38B and an operating loss of ¥0.15B (margin of △39.1%). Its scale is small, and its impact on consolidated results is limited. Consolidated profit is highly dependent on the core business.
Key Financial Indicators
【Profitability】The operating margin was 29.0%, the gross margin was 43.1%, and annualized ROE was 20.4%. Basic EPS was ¥91.33 (¥62.13 in the prior-year period, +47.0%), primarily reflecting the higher margins. 【Cash Quality】Cash and deposits were ¥86.38B (¥74.34B at the end of the prior-year period), exceeding short-term borrowings of ¥17.55B. Accounts receivable increased to ¥36.81B from ¥32.41B at the end of the prior-year period. Among inventories, raw materials and work in process accumulated to ¥32.54B and ¥14.25B, respectively, while finished goods declined to ¥4.56B. 【Investment Efficiency】The annualized total asset turnover ratio was approximately 0.73x, while ROE was supported by profitability. 【Financial Soundness】The equity ratio was 71.5%, the current ratio was approximately 382%, and net cash after deducting interest-bearing debt was approximately ¥54.8B. Long-term borrowings increased to ¥14.01B from ¥8.21B at the end of the prior-year period.
Cash Flow Analysis
No cash flow statement was disclosed. Based on the balance sheet, cash and deposits increased by approximately ¥12B from the end of the prior-year period to ¥86.38B. Retained earnings accumulated to ¥128.66B, up from ¥115.77B at the end of the prior-year period, with retained earnings supporting funding. Meanwhile, accounts receivable increased by ¥4.4B, raw materials by ¥5.9B, and work in process by ¥2.17B, tying up funds in working capital. Accounts payable increased by ¥4.27B, partially easing the funding burden. Long-term borrowings also increased by ¥5.8B, indicating that the increase in cash on hand was supported by borrowings in addition to business earnings.
Earnings Quality
Ordinary income of ¥24.54B exceeded operating income of ¥23.1B by ¥1.44B, primarily due to foreign exchange gains of ¥1.59B. These gains represented a reversal from foreign exchange losses of ¥2.37B in the prior-year period and are a non-operating factor that fluctuates depending on exchange rates. Meanwhile, operating income itself increased by ¥6.88B YoY, meaning that most of the earnings growth came from the core business. Extraordinary losses were primarily the ¥2.16B litigation settlement loss, which is largely temporary in nature. Income taxes were ¥6.46B, representing a 28.9% burden relative to profit before tax. Comprehensive income was ¥19.02B, with foreign currency translation adjustments of +¥3.21B contributing to the amount exceeding net income. Net income was ¥15.92B, and earnings are affected by foreign exchange movements.
Earnings Forecast and Guidance
The full-year forecast is revenue of ¥180.01B, operating income of ¥53.08B, ordinary income of ¥54.89B, and net income attributable to owners of parent of ¥37.78B; the forecast was revised during the current quarter. Interim results represent 44.3% of the revenue forecast, 43.5% of the operating income forecast, 44.7% of the ordinary income forecast, and 41.9% of the net income forecast. To meet the forecast, the second half will require revenue of approximately ¥100.27B and operating income of approximately ¥29.82B, equivalent to increases of approximately 25.8% and 29.1%, respectively, over the first half. The plan is weighted toward the second half, making the maintenance of profitability a key focus.
The forecast full-year operating margin is 29.5%, nearly in line with the first-half margin of 29.0%. Whether second-half revenue growth can be achieved without materially eroding margins is the key condition for meeting the plan.
Shareholder Returns
The Q2-end dividend was ¥0, and the full-year dividend forecast is ¥28; the dividend forecast was revised during the current quarter. The forecast payout ratio is approximately 12.9%, based on forecast EPS of ¥217.84. Treasury shares totaled 2,968 thousand shares, and no share buyback was disclosed. With net cash of approximately ¥54.8B, the company has substantial financial capacity to fund dividends.
Risk Factors
-
Business concentration risk: The Semiconductor and FPD-Related Equipment Business accounts for 99.5% of revenue and the vast majority of segment profit. Changes in customers’ capital investment cycles could affect the sustainability of the 29.0% operating margin.
-
Geographic concentration and foreign exchange risk: The United States, China, and Taiwan account for approximately 80.5% of revenue, leaving the company susceptible to trade policies and export restrictions. Foreign exchange gains of ¥1.59B are a factor in fluctuations in ordinary income, compared with foreign exchange losses of ¥2.37B in the prior-year period.
-
Working capital and litigation risk: Raw materials of ¥32.54B, work in process of ¥14.25B, and accounts receivable of ¥36.81B have accumulated, increasing the risk of inventory and receivables remaining tied up if demand fluctuates. The ¥2.16B litigation settlement loss was recorded as an extraordinary loss. Short-term borrowings account for approximately 55.6% of interest-bearing debt, but are amply covered by cash.
Industry Benchmarks (Reference; Compiled by the Company)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating margin | 29.0% | 6.4% (3.1%–10.7%) | +22.6pt |
| Net income margin | 20.0% | 5.0% (2.3%–8.6%) | +15.0pt |
Both the operating margin and net income margin are substantially above the upper bound of the industry IQR.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue growth rate (YoY) | 21.5% | 1.8% (-3.1%–7.5%) | +19.7pt |
The revenue growth rate is well above the upper bound of the industry IQR.
※Source: Company compilation
Key Points to Note in the Results
-
Operating income increased 42.4%, approximately twice the revenue growth rate of 21.5%, and the operating margin expanded by approximately 4.3pt, from 24.7% to 29.0%. Annualized ROE of 20.4% was primarily attributable to improved margins, not increased financial leverage.
-
The increase in ordinary income includes foreign exchange gains of ¥1.59B, while net income was reduced by the ¥2.16B litigation settlement loss. The core earnings performance should be distinguished from temporary factors.
-
The full-year forecast is weighted toward the second half, requiring operating income to increase by approximately 29.1% over the first half. The accumulation of raw materials, work in process, and accounts receivable is also an area to monitor for working capital trends.
Theoretical Share Value (Reference)
| Scenario | Theoretical value per share |
|---|---|
| Bear | ¥1,334 |
| Base | ¥1,411 |
| Bull | ¥1,527 |
| Assumption | Value |
|---|---|
| Book value per share (BPS) | ¥899 |
| Adjusted forecast EPS | ¥233.4 |
| Cost of equity r | 9.49% (10-year JGB 2.99% + equity risk premium 6.00% + size premium 0.50%) |
| Residual income persistence ω / explicit forecast | 0.62 / 5 years |
| Assumed payout ratio | 12.8% |
| Forecast EPS reliability adjustment | ×1.071 (based on historical guidance achievement in the same sector) |
| Implied P/B / P/E | 1.57x / 6.0x |
Sensitivity: ¥1,368 to ¥1,455 for cost of equity ±1%; ¥1,396 to ¥1,433 for ω ±0.1.
Notes:
- Net assets are taken at the quarter end (there is a timing gap with the full-year forecast).
- Net assets include non-controlling interests, so the estimate may be somewhat high.
(Model: residual income model (Ohlson-type, explicit 5-year fade) / rate reference month: 2026-09 / a mechanical estimate from public data only; it is not a forecast of the market price or a recommendation of any investment action, and it does not predict or guarantee future share prices)
This report is an automatically generated earnings analysis based on AI analysis of XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly available financial results data. Investment decisions should be made at your own responsibility and, where appropriate, after consulting a professional.
---End of Report---